Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Peptides Useful in the Treatment of Dyslipidemic and Vascular Disorders Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before July 11, 2005 will be considered.
View Prospective Grant of an Exclusive License: Cancer Diagnostic Based on Detecting Expression of Human Brother of Regulator of Imprinted Sites (“BORIS”) and BORIS Antibodies Only written comments and/or license applications which are received by the National Institutes of Health on or before July 5, 2005 will be considered.
View Prospective Grant of Exclusive License: Use of Human Papilloma Virus (HPV) Immunoreactive Peptides for the Development of Vaccines Against HPV Infections Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 5, 2005 will be considered.
View Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 27, 2005 will be considered.
View Prospective Grant of Exclusive License: Human Anesthetic Formulation Based Upon Cyclodextrin Carriers Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before July 19, 2005 will be considered.
View Prospective Grant of Exclusive License: Methods for Treating Inflammatory Bowel Disease Using Cholera Toxin B Subunit Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 14, 2005, will be considered.
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Retinopathy Only written comments and/or license applications which are received by the National Institutes of Health on or before June 14, 2005, will be considered.
View Prospective Grant of Exclusive License: Methods for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors as Applied to the Treatment of Human Cancer and Tumors Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before June 10, 2005 will be considered.
View Best Practices for the Licensing of Genomic Inventions: Final Notice
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of an Exclusive License: Novel Isosteric Thalidomide Analogs With Enhanced TNF-α Inhibitory Activity Only written comments and/or license applications which are received by the National Institutes of Health on or before May 9, 2005 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of 3-deazaneplanocin A and Cyclopentenyl Cytosine for the Development of the Topical Treatment of Basal Cell Carcinoma and Resistant Herpes Simplex Virus Infections Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before April 5, 2005, will be considered.
View Prospective Grant of Exclusive License: Commercializing Instruments, Reagents and Related Products Used for Template-Dependent Sequencing-by-Synthesis of Nucleic Acids at the Single Molecule Level, Wherein a Polymerase Carries the Donor Label Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before April 1, 2005, will be considered.
View Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Autoimmune Disease Only written comments and/or license applications which are received by the National Institutes of Health on or before March 28, 2005, will be considered.
View National Heart, Lung, and Blood Institute (NHLBI); Opportunity for a Cooperative Research and Development Agreement (CRADA) to Identify and Explore Epigenetic Regulatory Elements for Diagnostic and Therapeutics Purposes CRADA capability statements should be submitted to Vincent Kolesnitchenko, Ph.D., Technology Transfer Specialist, National Heart, Lung, and Blood Institute (NHLBI), Office of Technology Transfer and Development, National Institutes of Health, 6705 Rockledge Drive, Suite 6018, MSC 7992, Bethesda, MD 20892-7992; Phone: (301) 594-4115; Fax: (301) 594-3080; E-mail: vk5q@nih.gov. Capability statements must be received on or before March 28, 2005.
View Annual Comprehensive List of Guidance Documents at the Food and Drug Administration We welcome general comments on this list and on agency guidance documents at any time.
View Prospective Grant of an Exclusive License: “Vasostatin as Marrow Protectant” and “Use of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor Growth” Only written comments and/or license applications which are received by the National Institutes of Health on or before March 4, 2005 will be considered.
View Prospective Grant of Exclusive License: 4′ and 4′,4″-substituted-3-α-(diphenylmethoxy) Tropane Analogs as Cocaine Therapeutics Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 18, 2005, will be considered.
View Prospective Grant of Exclusive License: Dendrimer Based MRI Contrast Agents Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 1, 2005 will be considered.
View Prospective Grant of Exclusive License: Conformationally Locked Nucleoside Analogs Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 24, 2005 will be considered.
View Best Practices for the Licensing of Genomic Inventions Comments must be received no later than January 18, 2005.
View Prospective Grant of Exclusive License: Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3′-UTR of Dengue Types 1,2,3, And 4 Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 28, 2004, will be considered.
View Prospective Grant of Exclusive License: Human Parvovirus B19 Vaccine Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 19, 2005, will be considered.